Pulmonary Vascular Disease News

Short sleep duration, with and without self-reported insomnia, was predictive of elevated blood pressure and hypertension among adolescents, a speaker reported.

The incidence rate of pulmonary embolism-related hospitalizations in pediatric patients revealed that this outcome occurred infrequently; however, having acute PE raised the odds for in-hospital mortality, according to study findings.

In part 2, we dig into the history of pulmonary hypertension. How did this strange diagnosis first get recognized, what does it have to do with cows with thick necks and urinary catheters in the heart?

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular Research Institute 2025 Annual Congress.

In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up!

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous trials, according to a press release.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results.

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.

There has been little research on optimal treatments for pediatric patients with pulmonary arterial hypertension, but the Kids MoD PAH Trial is expected to change this by clearing up if sildenafil plus bosentan or sildenafil only is better.